The study was designed and approved in 2007, when guidelines recommended ACTH as a first-line treatment and reported ACTH as probably effective (Level I evidence), and probably more effective than VGB, which was considered the first choice only for IESS due to tuberous sclerosis (12). Here, POMC is linked to tuberous sclerosis.